EWTX

DEFA14A - Edgewise Therapeutics, Inc. (0001710072) (Filer)

DEF 14A - Edgewise Therapeutics, Inc. (0001710072) (Filer)

4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)

4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)

BOULDER, Colo., April 1, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (NASDAQ:EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions, today announced that on March 31, 2026, Edgewise granted inducement stock options to purchase a total of 72,000 shares of Edgewise's common stock to 4 new non-executive employees in connection with the commencement of their employment, pursuant to Edgewise's 2024 Inducement Equity Incentive Plan (the "Inducement Plan"). Each

4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)

4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)

144 - Edgewise Therapeutics, Inc. (0001710072) (Subject)

–The MESA data show stabilization of function in participants on sevasemten versus the predicted functional decline observed in Becker natural history studies –– Data reinforce prior clinical findings of sevasemten in Becker, a rare disease with no approved treatments ––The GRAND CANYON placebo-controlled pivotal cohort is on track to readout in 4Q 2026 –BOULDER, Colo., March 10, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (NASDAQ:EWTX), a leading muscle disease biopharmaceutical company, today presented at the 2026 MDA Clinical and Scientific Conference, long-term data from its MESA open-label extension study of sevasemten in Becker muscular dystrophy (Becker), a devastating genetic di

BOULDER, Colo., March 4, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (NASDAQ:EWTX), a leading muscle disease biopharmaceutical company, today announced that Edgewise leadership will present at the Leerink Global Healthcare Conference on Wednesday, March 11, 2026, at 1:40 p.m. ET. The presentation will be webcast live; a link for the webcast can be found on the Edgewise Events & Presentations page and will be accessible for replay for a limited time following the conference. It is recommended that users connect to the live webcast several minutes prior to the start to ensure

BOULDER, Colo., March 3, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (NASDAQ:EWTX), a leading muscle disease biopharmaceutical company, today announced its participation at the 2026 Muscular Dystrophy Association (MDA) Clinical and Scientific Conference. The Company will host a lunch forum with experts presenting Becker natural history data and discussing the need for community and definition of care. New sevasemten data in Becker will also be presented at the conference including from the MESA open-label extension trial. The conference will take place at the Hilton Orlando in Orlando, Fla., from March 8–11, 2026.

BOULDER, Colo., March 2, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (NASDAQ:EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions, today announced that on February 27, 2026, Edgewise granted inducement stock options to purchase a total of 51,000 shares of Edgewise's common stock to 3 new non-executive employees in connection with the commencement of their employment, pursuant to Edgewise's 2024 Inducement Equity Incentive Plan (the "Inducement Plan"). Ea

10-K - Edgewise Therapeutics, Inc. (0001710072) (Filer)

8-K - Edgewise Therapeutics, Inc. (0001710072) (Filer)

–  CIRRUS-HCM 12-week data of EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) expected in H1 2026  ––  Phase 1 healthy adult trial data of EDG-15400 and plans for heart failure studies expected in H1 2026  ––  Pivotal GRAND CANYON results for sevasemten in Becker muscular dystrophy (Becker) expected in Q4 2026  –BOULDER, Colo., Feb. 26, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (NASDAQ:EWTX), a leading muscle disease biopharmaceutical company, today reported financial results for the fourth quarter and full year of 2025 and recent business highlights.

BOULDER, Colo., Feb. 5, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc., (NASDAQ:EWTX), a leading muscle disease biopharmaceutical company, today announced that Behrad Derakhshan, Ph.D., Chief Operating Officer, will present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Thursday, February 12, 2026 at 3:00 pm ET. The presentation will be webcast live; a link for the webcast can be found on the Edgewise Events & Presentations page and will be accessible for replay, for a limited time, following the conference. It is recommended that users connect to the live webcas

BOULDER, Colo., Feb. 2, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (NASDAQ:EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions, today announced that on January 30, 2025, Edgewise granted inducement stock options to purchase a total of 198,250 shares of Edgewise's common stock to 7 new non-executive employees in connection with the commencement of their employment, pursuant to Edgewise's 2024 Inducement Equity Incentive Plan (the "Inducement Plan").    

4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)

144 - Edgewise Therapeutics, Inc. (0001710072) (Subject)

144 - Edgewise Therapeutics, Inc. (0001710072) (Subject)

- Advancing robust clinical pipeline of novel therapeutics for muscular dystrophies and serious cardiac conditions - - Presenting at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026 at 8:15 am PT (11:15 am ET) - BOULDER, Colo., Jan. 13, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc., (NASDAQ:EWTX), a leading muscle disease biopharmaceutical company, today provided updates on the Company's clinical programs and highlighted major milestones for 2026. Edgewise Chief Executive Officer, Kevin Koch, Ph.D., will present these updates today at the J.P. Morgan 2026 Healthcare Conference.

BOULDER, Colo., Jan. 6, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc., (NASDAQ:EWTX), a leading muscle disease biopharmaceutical company, today announced that Kevin Koch, Ph.D., President and Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference. Event Details: Date: Tuesday, January 13, 2026 Time: 8:15 am PT (11:15 am ET) The presentation will be webcast live; a link for the webcast can be found on the Edgewise Events & Presentations page and will be accessible for replay, for a limited time, following the conference. It is recommended

4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)

BOULDER, Colo., Jan. 5, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (NASDAQ:EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions, today announced that on December 31, 2025, Edgewise granted inducement stock options to purchase a total of 119,250 shares of Edgewise's common stock to 4 new non-executive employees in connection with the commencement of their employment, pursuant to Edgewise's 2024 Inducement Equity Incentive Plan (the "Inducement Plan").

144 - Edgewise Therapeutics, Inc. (0001710072) (Subject)